BRPI1013588A2 - composição - Google Patents

composição

Info

Publication number
BRPI1013588A2
BRPI1013588A2 BRPI1013588A BRPI1013588A BRPI1013588A2 BR PI1013588 A2 BRPI1013588 A2 BR PI1013588A2 BR PI1013588 A BRPI1013588 A BR PI1013588A BR PI1013588 A BRPI1013588 A BR PI1013588A BR PI1013588 A2 BRPI1013588 A2 BR PI1013588A2
Authority
BR
Brazil
Prior art keywords
composition
Prior art date
Application number
BRPI1013588A
Other languages
English (en)
Inventor
Christopher Herring
Laurent S Jespers
Lucy J Holt
Malgorzata Pupecka-Swider
Sebastian Mayer
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42308293&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1013588(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI1013588A2 publication Critical patent/BRPI1013588A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
BRPI1013588A 2009-03-27 2010-03-24 composição BRPI1013588A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16391709P 2009-03-27 2009-03-27
PCT/EP2010/053806 WO2010108937A2 (en) 2009-03-27 2010-03-24 Drug fusions and conjugates

Publications (1)

Publication Number Publication Date
BRPI1013588A2 true BRPI1013588A2 (pt) 2016-04-19

Family

ID=42308293

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013588A BRPI1013588A2 (pt) 2009-03-27 2010-03-24 composição

Country Status (24)

Country Link
US (2) US8779103B2 (pt)
EP (1) EP2411054A2 (pt)
JP (1) JP2012521971A (pt)
KR (1) KR20110137819A (pt)
CN (2) CN104127880A (pt)
AR (1) AR076147A1 (pt)
AU (1) AU2010227552B2 (pt)
BR (1) BRPI1013588A2 (pt)
CA (1) CA2756853A1 (pt)
CL (1) CL2011002387A1 (pt)
CO (1) CO6361953A2 (pt)
DO (1) DOP2011000288A (pt)
EA (1) EA021146B1 (pt)
IL (1) IL215200A0 (pt)
MA (1) MA33221B1 (pt)
MX (1) MX2011010151A (pt)
NZ (1) NZ595344A (pt)
PE (1) PE20120514A1 (pt)
SG (1) SG174497A1 (pt)
TW (1) TW201100104A (pt)
UA (1) UA98911C2 (pt)
UY (1) UY32514A (pt)
WO (1) WO2010108937A2 (pt)
ZA (1) ZA201107022B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ595344A (en) * 2009-03-27 2013-09-27 Glaxo Group Ltd Drug fusions and conjugates
CN104147611A (zh) * 2009-09-30 2014-11-19 葛兰素集团有限公司 具有延长的半衰期的药物融合体和缀合物
CA2799633A1 (en) * 2010-05-20 2011-11-24 Elena De Angelis Improved anti-serum albumin binding variants
SG185428A1 (en) 2010-06-08 2012-12-28 Genentech Inc Cysteine engineered antibodies and conjugates
EP2621953B1 (en) 2010-09-30 2017-04-05 Ablynx N.V. Biological materials related to c-met
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
WO2012136790A1 (en) * 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
KR20220114104A (ko) 2011-06-23 2022-08-17 아블린쓰 엔.브이. 면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법
HUE047238T2 (hu) * 2011-06-23 2020-04-28 Ablynx Nv Szérumalbuminhoz kötõdõ fehérjék
CN102949731A (zh) * 2011-09-16 2013-03-06 西藏海思科药业集团股份有限公司 与glp-2受体特异性结合的药物融合体
CN102949730A (zh) * 2011-09-16 2013-03-06 西藏海思科药业集团股份有限公司 特异结合glp-1受体的药物融合体
US9346884B2 (en) 2011-09-30 2016-05-24 Ablynx N.V. Biological materials related to c-Met
CN102827277B (zh) * 2012-04-26 2014-12-10 拜明(苏州)生物技术有限公司 抗人血清白蛋白单链抗体及其碳端连接多肽药物的方法
CN102875675B (zh) * 2012-04-26 2015-05-27 拜明(苏州)生物技术有限公司 抗人血清白蛋白单链抗体及其氮端连接多肽药物的方法
AU2014211438B2 (en) * 2013-01-31 2017-02-02 Glaxo Group Limited Method of producing a protein
MX369656B (es) 2014-01-20 2019-11-15 Hanmi Pharm Ind Co Ltd Insulina de accion prolongada y uso de la misma.
SG11201606684YA (en) * 2014-02-21 2016-09-29 Medimmune Llc Anti-pcsk9~glp-1 fusions and methods for use
EP3693386A1 (en) 2014-05-16 2020-08-12 Ablynx NV Immunoglobulin variable domains
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
SG11201701128YA (en) * 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
UY36870A (es) 2015-08-28 2017-03-31 Hanmi Pharm Ind Co Ltd Análogos de insulina novedosos
TWI774694B (zh) 2016-09-23 2022-08-21 南韓商韓美藥品股份有限公司 具有降低對胰島素受體之親和力之胰島素類似物及其用途
CN107281471A (zh) * 2017-06-26 2017-10-24 中国药科大学 一种改构的胰高血糖素样肽－1及其修饰物的应用
AR111341A1 (es) 2017-03-23 2019-07-03 Hanmi Pharm Ind Co Ltd Un conjugado del análogo de insulina con afinidad reducida para el receptor de insulina y uso del mismo
TWI809515B (zh) 2017-12-21 2023-07-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TWI810937B (zh) 2017-12-21 2023-08-01 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
WO2019243502A1 (en) 2018-06-21 2019-12-26 Novo Nordisk A/S Novel compounds for treatment of obesity
CN111234015B (zh) * 2020-02-12 2021-04-06 康维众和(中山)生物药业有限公司 用于延长药物半衰期的抗体、其融合蛋白和应用
WO2021182928A1 (ko) * 2020-03-12 2021-09-16 주식회사 에스엘메타젠 신규 이중 특이성 단백질 및 그의 용도
WO2022015039A1 (ko) * 2020-07-14 2022-01-20 (주)지아이이노베이션 글루카곤-유사 펩타이드-1 및 글루카곤-유사 펩타이드-2를 포함하는 융합 단백질 및 이의 용도

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ222907A (en) 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
WO1990011296A1 (en) 1989-03-20 1990-10-04 The General Hospital Corporation Insulinotropic hormone
DE69129226T2 (de) 1990-01-24 1998-07-30 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
DK36492D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
ES2319936T5 (es) 1996-08-08 2013-06-24 Amylin Pharmaceuticals, Inc. Regulación de la motilidad gastrointestinal
CA2792122C (en) 1997-07-07 2015-09-08 Medical Research Council In vitro sorting method
EP1019077B2 (en) 1997-08-08 2010-12-22 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
DE69838916T2 (de) 1997-11-14 2008-12-18 Amylin Pharmaceuticals, Inc., San Diego Neuartige exendin agonisten
ATE383867T1 (de) 1997-11-14 2008-02-15 Amylin Pharmaceuticals Inc Neuartige exendin agonisten
DE69936446T2 (de) 1998-02-13 2008-03-06 Amylin Pharmaceuticals, Inc., San Diego Inotropische und diuretische effekte von exendin und glp-1
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
BR0116024A (pt) 2000-12-07 2005-12-13 Lilly Co Eli Proteìna de fusão heteróloga e uso da mesma
EP1412384B1 (en) 2001-06-28 2007-12-26 Novo Nordisk A/S Stable formulation of modified glp-1
EP1463751B1 (en) 2001-12-21 2013-05-22 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
EP1463752A4 (en) 2001-12-21 2005-07-13 Human Genome Sciences Inc ALBUMIN FUSION PROTEINS
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
WO2005027978A2 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
KR20070039911A (ko) * 2004-06-01 2007-04-13 도만티스 리미티드 증강된 혈청 반감기를 가지는 이특이성 융합 항체
US20060052301A1 (en) 2004-06-03 2006-03-09 Ronen Shemesh Splice variants of peptide YY, neuropeptide Y, pancreatic peptide Y and Amylin, and uses thereof
NZ555464A (en) * 2004-12-02 2010-03-26 Domantis Ltd Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
GB0724331D0 (en) * 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
JP2011517561A (ja) * 2008-03-31 2011-06-16 グラクソ グループ リミテッド 薬物融合体および複合体
ES2655071T3 (es) * 2009-02-19 2018-02-16 Glaxo Group Limited Variantes de unión de anti-albúmina de suero mejoradas
UY32452A (es) * 2009-02-19 2010-09-30 Glaxo Group Ltd Variantes de unión a anti-albúmina de suero mejoradas
NZ595344A (en) * 2009-03-27 2013-09-27 Glaxo Group Ltd Drug fusions and conjugates
CN104147611A (zh) * 2009-09-30 2014-11-19 葛兰素集团有限公司 具有延长的半衰期的药物融合体和缀合物

Also Published As

Publication number Publication date
CN104127880A (zh) 2014-11-05
CL2011002387A1 (es) 2012-07-20
MA33221B1 (fr) 2012-04-02
WO2010108937A2 (en) 2010-09-30
KR20110137819A (ko) 2011-12-23
WO2010108937A3 (en) 2010-11-25
CA2756853A1 (en) 2010-09-30
CO6361953A2 (es) 2012-01-20
AU2010227552B2 (en) 2015-02-26
IL215200A0 (en) 2011-12-29
AR076147A1 (es) 2011-05-18
SG174497A1 (en) 2011-10-28
EA201190184A1 (ru) 2012-05-30
MX2011010151A (es) 2011-12-14
EA021146B1 (ru) 2015-04-30
CN102481373A (zh) 2012-05-30
PE20120514A1 (es) 2012-05-14
TW201100104A (en) 2011-01-01
AU2010227552A1 (en) 2011-11-03
ZA201107022B (en) 2013-03-27
US20120100141A1 (en) 2012-04-26
UA98911C2 (uk) 2012-06-25
UY32514A (es) 2010-10-29
EP2411054A2 (en) 2012-02-01
US20140193407A1 (en) 2014-07-10
NZ595344A (en) 2013-09-27
JP2012521971A (ja) 2012-09-20
US8779103B2 (en) 2014-07-15
DOP2011000288A (es) 2012-01-15

Similar Documents

Publication Publication Date Title
SMT201600307B (it) Composizione liposomiale
BRPI1013588A2 (pt) composição
DK3078664T3 (da) Antiparasitiske dihydroazol-sammensætninger
UY33161A (es) Composiciones plaguicidas
BRPI1015474A2 (pt) composição
DK2414015T3 (da) Laryngoskopsystem
DE112010004215A5 (de) Hydrostataktor
DE112010002949A5 (de) Kupplungstastpunkte
DK2411442T4 (da) Umættet polyesterresin
BRPI1008774A2 (pt) espiroamida substituída
DOP2011000396A (es) Composiciones novedosas
BRPI1008827A2 (pt) deisobutenizador
DK2430035T3 (da) Uracylspipooxetannukleosider
BRPI1014968A2 (pt) subalargador
DE112010002728A5 (de) Turboinhalator
BRPI1010690A2 (pt) composições
DE112009005323A5 (de) Hebelarmprüfmaschine
DE112010004249A5 (de) Spindelaktor
DE112009005462T8 (de) Lenkungsssteuervorrichtung
BRPI1008070A2 (pt) tricianoboratos
DK2483126T3 (da) Skinnekøretøj
BRPI1005290A2 (pt) composição
DE112010004865T8 (de) Lamellennassreibkupplung
DK2506968T3 (da) Faujasit-zeolit
DE112010003255A5 (de) Fördergutverteiler

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE. PAGAR RESTAURACAO.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C07K 14/605 (2006.01), A61K 38/26 (2006.0

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2471 DE 15/05/2018.